
Sign up to save your podcasts
Or


Send us a text
Bill Taranto is President of the Merck Global Health Innovation Fund ( MGHIF - https://www.msdghifund.com/ ).
The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck’s core business of discovering, developing and marketing innovative drugs and vaccines.
Bill has more than three decades of experience in the healthcare industry.
MGHIF is a $750m evergreen fund focused on identifying opportunities that are adjacent to Merck’s core business of pharmaceuticals and vaccines. Under Bill's leadership, MGHIF has invested more than $1bn in 70 companies, with more than $7bn in exits.
Prior to joining Merck, Bill spent 18 years at Johnson & Johnson (J&J) in various roles. As VP of healthcare strategy and venture at J&J, he was responsible for evaluating and creating new healthcare business models through venture capital and acquisitions.
Prior to joining J&J, Bill spent eight years in investment banking.
#BillTaranto #MerckGlobalHealthInnovationFund #Scale #Impact #InvestmentBanking #DrugDiscovery #ClinicalDevelopment #Manufacturing #SupplyChain #RealWorldEvidence #CorporateVentureCapital #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast
Support the show
By Ira Pastor5
44 ratings
Send us a text
Bill Taranto is President of the Merck Global Health Innovation Fund ( MGHIF - https://www.msdghifund.com/ ).
The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck’s core business of discovering, developing and marketing innovative drugs and vaccines.
Bill has more than three decades of experience in the healthcare industry.
MGHIF is a $750m evergreen fund focused on identifying opportunities that are adjacent to Merck’s core business of pharmaceuticals and vaccines. Under Bill's leadership, MGHIF has invested more than $1bn in 70 companies, with more than $7bn in exits.
Prior to joining Merck, Bill spent 18 years at Johnson & Johnson (J&J) in various roles. As VP of healthcare strategy and venture at J&J, he was responsible for evaluating and creating new healthcare business models through venture capital and acquisitions.
Prior to joining J&J, Bill spent eight years in investment banking.
#BillTaranto #MerckGlobalHealthInnovationFund #Scale #Impact #InvestmentBanking #DrugDiscovery #ClinicalDevelopment #Manufacturing #SupplyChain #RealWorldEvidence #CorporateVentureCapital #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast
Support the show

14,318 Listeners

3,407 Listeners

6,407 Listeners

112,236 Listeners

322 Listeners

33 Listeners

40,343 Listeners

29,185 Listeners